Stocks Health care VRAX
NASDAQ · Health careVirax Biolabs Group Ltd (VRAX)
Virax Biolabs Group Ltd reported revenue of $6.3K in fiscal 2025, down 96.0% from a year earlier. It posted a net loss of $6.1M. In fiscal 2025 capital spending exceeded operating cash flow by $5.2M. At March 31, 2025 it held $4.2M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on July 6, 2026.
What Virax Biolabs Group Ltd does
Virax Biolabs Group Ltd is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker VRAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.3K | -$6.1M | -$1.62 | -$5.2M |
| 2024 | $156.4K | -$6.7M | -$3.36 | -$7.2M |
| 2023 | $8.6K | -$5.5M | -$5.13 | n/a |
| 2022 | $0 | -$1.7M | -$1.79 | n/a |
| 2022 | $123.8K | -$651K | n/a | n/a |
Full financial statements: income, balance sheet and cash flow
Where VRAX ranks in Health care
Latest SEC filings
What Virax Biolabs Group Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026
- September 4, 2026
- September 4, 2026
- September 2, 2026Form F-3/A filing F-3/A
- August 26, 2026
- August 18, 2026
- July 31, 2026
- July 24, 2026Form F-3 filing F-3
- July 16, 2026
- July 10, 2026
Questions about VRAX
What does Virax Biolabs Group Ltd do?
Virax Biolabs Group Ltd is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker VRAX.
Is Virax Biolabs Group Ltd profitable?
No. In fiscal 2025 it reported a net loss of $6.1M on revenue of $6.3K.
How much revenue does Virax Biolabs Group Ltd make?
In fiscal 2025 Virax Biolabs Group Ltd reported revenue of $6.3K. That is 96.0% less than a year earlier.
When did Virax Biolabs Group Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on July 6, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the securities offering prospectus from September 10, 2026.
Similar companies
Compare VRAX with
Follow VRAX
Get an email when Virax Biolabs Group Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow VRAX: get an email when it filesWhere the numbers come from
Financial figures are the values Virax Biolabs Group Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.